



# Provisional agenda

## PLENARY

### **1. Opening of the Health Assembly**

- 1.1 Appointment of the Committee on Credentials
- 1.2 Election of the President
- 1.3 Election of the five Vice-Presidents, the Chairmen of the main committees, and establishment of the General Committee
- 1.4 Adoption of the agenda and allocation of items to the main committees

Document A71/1

### **2. Report of the Executive Board on its 141st and 142nd sessions, and on its special session on the draft thirteenth general programme of work, 2019–2023**

Document [A71/2](#)

### **3. Address by Dr Tedros Adhanom Ghebreyesus, Director-General**

Document A71/3

### **4. Invited speakers**

### **5. Admission of new Members and Associate Members [if any]**

### **6. Executive Board: election**

### **7. Awards**

Document [A71/INF./1](#)

### **8. Reports of the main committees**

### **9. Closure of the Health Assembly**

## COMMITTEE A

### 10. Opening of the Committee<sup>1</sup>

### 11. Strategic priority matters

#### 11.1 Draft thirteenth general programme of work, 2019–2023

Documents [A71/4](#), A71/4 Add.1 and EB142/2018/REC/1, resolution EB142.R2

#### 11.2 Public health preparedness and response

- Report of the Independent Oversight and Advisory Committee for the WHO Health Emergencies Programme

Document [A71/5](#)

- WHO's work in health emergencies<sup>2</sup>

Document [A71/6](#)

- Implementation of the International Health Regulations (2005)

Documents [A71/7](#), [A71/8](#) and EB142/2018/REC/1, decision EB142(1)

#### 11.3 Polio transition and post-certification

Document [A71/9](#)

#### 11.4 Health, environment and climate change

Documents [A71/10](#), [A71/10 Add.1](#) and [A71/11](#)

#### 11.5 Addressing the global shortage of, and access to, medicines and vaccines

Documents [A71/12](#) and EB142/2018/REC/1, decision EB142(3)

#### 11.6 Global strategy and plan of action on public health, innovation and intellectual property

Documents [A71/13](#) and EB142/2018/REC/1, decision EB142(4)

#### 11.7 Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018

Documents [A71/14](#) and [A71/14 Add.1](#)

---

<sup>1</sup> Including election of Vice-Chairmen and Rapporteur.

<sup>2</sup> The Director-General's report will also cover cholera prevention.

11.8 Preparation for a high-level meeting of the General Assembly on ending tuberculosis

Documents [A71/15](#), [A71/16](#), A71/16 Add.1 and EB142/2018/REC/1, resolution EB142.R3

**12. Other technical matters**

12.1 Global snakebite burden

Documents [A71/17](#) and EB142/2018/REC/1, resolution EB142.R4

12.2 Physical activity for health

Documents [A71/18](#) and EB142/2018/REC/1, resolution EB142.R5

12.3 Global Strategy for Women's, Children's and Adolescents' Health (2016–2030): sexual and reproductive health, interpersonal violence, and early childhood development

Document [A71/19](#)

12.4 mHealth

Document [A71/20](#)

12.5 Improving access to assistive technology

Documents [A71/21](#) and EB142/2018/REC/1, resolution EB142.R6

12.6 Maternal, infant and young child nutrition

- Comprehensive implementation plan on maternal, infant and young child nutrition: biennial report

Document [A71/22](#)

- Safeguarding against possible conflicts of interest in nutrition programmes

Document [A71/23](#)

12.7 Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits

Documents [A71/24](#), [A71/24 Add.1](#) and [A71/42](#)

12.8 Rheumatic fever and rheumatic heart disease

Documents [A71/25](#) and EB141/2017/REC/1, resolution EB141.R1

12.9 Eradication of poliomyelitis

Document [A71/26](#), [A71/26 Add.1](#) and [A71/26 Add.2](#)

**COMMITTEE B**

**13. Opening of the Committee<sup>1</sup>**

**14. Health conditions in the occupied Palestinian territory, including East Jerusalem, and in the occupied Syrian Golan**

Document [A71/27](#)

**15. Programme budget and financial matters**

15.1 WHO programmatic and financial reports for 2016–2017, including audited financial statements for 2017

Documents [A71/28](#), [A71/29](#) and [A71/INF./2](#)

15.2 Financing of the Programme budget 2018–2019

Document [A71/30](#)

15.3 Status of collection of assessed contributions, including Member States in arrears in the payment of their contributions to an extent that would justify invoking Article 7 of the Constitution

Document [A71/31](#)

15.4 Special arrangements for settlement of arrears [if any]

15.5 Assessment of new Members and Associate Members [if any]

15.6 Amendments to the Financial Regulations and Financial Rules [if any]

**16. Audit and oversight matters**

16.1 Report of the External Auditor

Document [A71/32](#)

---

<sup>1</sup> Including election of Vice-Chairmen and Rapporteur.

16.2 Report of the Internal Auditor

- Annual report

Document [A71/33](#)

- External and internal audit recommendations: progress on implementation

Document A71/34

**17. Staffing matters**

17.1 Human resources: annual report

Document [A71/35](#)

17.2 Report of the International Civil Service Commission

Document [A71/36](#)

17.3 Amendments to the Staff Regulations and Staff Rules

Documents [A71/37](#) and EB142/2018/REC/1, resolutions EB142.R8 and EB142.R9

17.4 Appointment of representatives to the WHO Staff Pension Committee

Document [A71/38](#)

**18. Management and legal matters**

18.1 Agreements with intergovernmental organizations [if any]

**19. Collaboration within the United Nations system and with other intergovernmental organizations**

**20. Matters for information**

20.1 Global vaccine action plan

Document [A71/39](#)

20.2 Real estate: update on the Geneva buildings renovation strategy

Document [A71/40](#)

20.3 Progress reports

Document [A71/41](#)

### **Communicable diseases**

- A. Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, for the period 2016–2021 (resolution WHA69.22 (2016))
- B. Eradication of dracunculiasis (resolution WHA64.16 (2011))
- C. Elimination of schistosomiasis (resolution WHA65.21 (2012))

### **Noncommunicable diseases**

- D. Public health dimension of the world drug problem (decision WHA70(18) (2017))
- E. Global burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledge implications (resolution WHA68.20 (2015))
- F. Comprehensive mental health action plan 2013–2020 (resolution WHA66.8 (2013))
- G. Comprehensive and coordinated efforts for the management of autism spectrum disorders (resolution WHA67.8 (2014))

### **Promoting health through the life course**

- H. Global strategy and action plan on ageing and health 2016–2020: towards a world in which everyone can live a long and healthy life (resolution WHA69.3 (2016))

### **Health systems**

- I. Promoting the health of refugees and migrants (resolution WHA70.15 (2017))
- J. Strengthening integrated, people-centred health services (resolution WHA69.24 (2016))
- K. Promoting innovation and access to quality, safe, efficacious and affordable medicines for children (resolution WHA69.20 (2016))
- L. Sustainable health financing structures and universal coverage (resolution WHA64.9 (2011))
- M. Availability, safety and quality of blood products (resolution WHA63.12 (2010))
- N. Human organ and tissue transplantation (resolution WHA63.22 (2010))
- O. WHO strategy on research for health (resolution WHA63.21 (2010))
- P. Workers' health: global plan of action (resolution WHA60.26 (2007))

**Health emergencies programme**

Q. Smallpox eradication: destruction of variola virus stocks (resolution WHA60.1 (2007))

**Corporate services/enabling functions**

R. Multilingualism: implementation of action plan (resolution WHA61.12 (2008))

= = =